ARGENX $ARGX Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1,751M (Est. $1.66B) 🟢 🔹 Diluted EPS: $7.80 (Est. $7.95) 🔴; +51% YoY 🔹 Product Net Sales: $1,721M; +54% YoY 🔹 Operating Profit: $486M (Est. $556M) 🔴 FY26 Guide: 🔹 Combined R&D and SG&A: ~$4B Announcements: 🔹 VYVGART Hytrulo: sBLA in IMNM on track for submission by year-end 2026 🔹 EMPASSION: Topline results expected in December 2026 🔹 FB102: Advancing to Phase 3 in celiac disease Other Q3 Metrics: 🔹 Net Profit: $506M 🔹 R&D Expenses: $503M 🔹 SG&A Expenses: $598M 🔹 Cash & Current Financial Assets: $3.7B Key Updates: 🔹 Acquisition-Related Expenses: approximately $150M associated with the Forte Biosciences acquisition Comments: 🔸 “The positive results from our Phase 3 ALKIVIA study further reinforce the potential of VYVGART beyond neurology”